Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Gemtuzumab ozogamicin.

McGavin JK, Spencer CM.

Drugs. 2001;61(9):1317-22; discussion 1323-4. Review.

PMID:
11511025
2.
3.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

Bross PF, Beitz J, Chen G, Chen XH, Duffy E, Kieffer L, Roy S, Sridhara R, Rahman A, Williams G, Pazdur R.

Clin Cancer Res. 2001 Jun;7(6):1490-6. Erratum in: Clin Cancer Res 2002 Jan;8(1):300.

4.

Preliminary results of the safety of immunotherapy with gemtuzumab ozogamicin following reduced intensity allogeneic stem cell transplant in children with CD33+ acute myeloid leukemia.

Roman E, Cooney E, Harrison L, Militano O, Wolownik K, Hawks R, Foley S, Satwani P, Unal E, Bhatia M, Bradley B, Del Toro G, George D, Garvin J, van de Ven C, Cairo MS.

Clin Cancer Res. 2005 Oct 1;11(19 Pt 2):7164s-7170s.

5.

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse.

Sievers EL, Larson RA, Stadtmauer EA, Estey E, Löwenberg B, Dombret H, Karanes C, Theobald M, Bennett JM, Sherman ML, Berger MS, Eten CB, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group.

J Clin Oncol. 2001 Jul 1;19(13):3244-54.

PMID:
11432892
6.

Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.

Giles FJ.

Expert Rev Anticancer Ther. 2002 Dec;2(6):630-40. Review.

PMID:
12503209
7.

Current use and future development of gemtuzumab ozogamicin.

Larson RA.

Semin Hematol. 2001 Jul;38(3 Suppl 6):24-31. Review.

PMID:
11474494
8.

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

Arceci RJ, Sande J, Lange B, Shannon K, Franklin J, Hutchinson R, Vik TA, Flowers D, Aplenc R, Berger MS, Sherman ML, Smith FO, Bernstein I, Sievers EL.

Blood. 2005 Aug 15;106(4):1183-8. Epub 2005 May 10.

9.

Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin.

Duong HK, Sekeres MA.

Clin Interv Aging. 2009;4:197-205. Epub 2009 May 14. Review.

10.
11.

Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.

Stasi R.

Expert Opin Biol Ther. 2008 Apr;8(4):527-40. doi: 10.1517/14712598.8.4.527 . Review.

PMID:
18352855
12.

In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.

Petrich T, Korkmaz Z, Krull D, Frömke C, Meyer GJ, Knapp WH.

Eur J Nucl Med Mol Imaging. 2010 May;37(5):851-61. doi: 10.1007/s00259-009-1356-x. Epub 2010 Jan 27.

PMID:
20107790
13.

Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia.

Hamann PR, Hinman LM, Hollander I, Beyer CF, Lindh D, Holcomb R, Hallett W, Tsou HR, Upeslacis J, Shochat D, Mountain A, Flowers DA, Bernstein I.

Bioconjug Chem. 2002 Jan-Feb;13(1):47-58.

PMID:
11792178
14.

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

Larson RA, Boogaerts M, Estey E, Karanes C, Stadtmauer EA, Sievers EL, Mineur P, Bennett JM, Berger MS, Eten CB, Munteanu M, Loken MR, Van Dongen JJ, Bernstein ID, Appelbaum FR; Mylotarg Study Group.

Leukemia. 2002 Sep;16(9):1627-36.

15.

Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.

Candoni A, Martinelli G, Toffoletti E, Chiarvesio A, Tiribelli M, Malagola M, Piccaluga PP, Michelutti A, Simeone E, Damiani D, Russo D, Fanin R.

Leuk Res. 2008 Dec;32(12):1800-8. doi: 10.1016/j.leukres.2008.05.011. Epub 2008 Jul 14.

PMID:
18621416
16.

CD34(+)/CD38(-) stem cells in chronic myeloid leukemia express Siglec-3 (CD33) and are responsive to the CD33-targeting drug gemtuzumab/ozogamicin.

Herrmann H, Cerny-Reiterer S, Gleixner KV, Blatt K, Herndlhofer S, Rabitsch W, Jäger E, Mitterbauer-Hohendanner G, Streubel B, Selzer E, Schwarzinger I, Sperr WR, Valent P.

Haematologica. 2012 Feb;97(2):219-26. doi: 10.3324/haematol.2010.035006. Epub 2011 Oct 11.

17.

Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia.

Fenton C, Perry CM.

Drugs. 2005;65(16):2405-27. Review.

PMID:
16266206
18.

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.

Larson RA, Sievers EL, Stadtmauer EA, Löwenberg B, Estey EH, Dombret H, Theobald M, Voliotis D, Bennett JM, Richie M, Leopold LH, Berger MS, Sherman ML, Loken MR, van Dongen JJ, Bernstein ID, Appelbaum FR.

Cancer. 2005 Oct 1;104(7):1442-52.

19.

Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.

Unal S, Cakir M, Kuşkonmaz B, Cetin M, Tuncer AM.

Turk J Pediatr. 2009 Jan-Feb;51(1):69-71.

PMID:
19378895
20.

Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study.

Kobayashi Y, Tobinai K, Takeshita A, Naito K, Asai O, Dobashi N, Furusawa S, Saito K, Mitani K, Morishima Y, Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J, Miyawaki S, Naoe T, Usui N, Ohno R.

Int J Hematol. 2009 May;89(4):460-469. doi: 10.1007/s12185-009-0298-1. Epub 2009 Apr 10.

PMID:
19360457

Supplemental Content

Support Center